Tag: trebananib

1. Ovarian cancer patients randomized to receive paclitaxel + trebananib had improved progression-free survival versus paclitaxel + placebo.  2. Patients randomized to receive paclitaxel + trebananib demonstrated improved RECIST 1.1 and CA-125 scores.  Evidence Rating Level: 1 (Excellent)        Study Rundown: Epithelial ovarian cancer, which includes ovarian, fallopian tube, and...